Motif Bio Submits NDA for Iclaprim

June 14, 2018
Motif Bio plc

June 14, 2018: Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim, a targeted, Gram-positive investigational antibiotic,for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Press Release available here: